Quest Diagnostics ( NYSE:DGX – Get Rating) last announced its quarterly earnings results on Thursday, April 27th. The company has a current ratio of 1.34, a quick ratio of 1.20 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $15.52 billion, a P/E ratio of 20.44 and a beta of 0.95. Quest Diagnostics Incorporated has a 12-month low of $120.40 and a 12-month high of $158.34. The stock has a 50-day moving average price of $136.83 and a 200 day moving average price of $142.38.
According to data from MarketBeat, Quest Diagnostics has an average rating of “Hold” and an average target price of $151.20. Nine analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Finally, Mizuho restated a “buy” rating and issued a $165.00 price target on shares of Quest Diagnostics in a research report on Friday, March 17th. They issued a “hold” rating for the company. assumed coverage on Quest Diagnostics in a research report on Thursday, May 18th. Bank of America cut Quest Diagnostics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $166.00 to $148.00 in a research report on Tuesday, May 2nd. Citigroup upgraded Quest Diagnostics from a “sell” rating to a “neutral” rating and upped their price target for the stock from $125.00 to $142.00 in a research report on Monday, April 3rd.
Truist Financial reduced their price target on Quest Diagnostics from $170.00 to $160.00 and set a “hold” rating for the company in a research report on Friday, March 17th. Get Quest Diagnostics alerts:Ī number of analysts have commented on the company. Institutional investors own 87.39% of the company’s stock. Amundi now owns 1,475,354 shares of the medical research company’s stock worth $228,663,000 after buying an additional 105,471 shares in the last quarter. Finally, Amundi increased its position in Quest Diagnostics by 7.7% in the fourth quarter. Northern Trust Corp now owns 1,514,577 shares of the medical research company’s stock valued at $207,286,000 after acquiring an additional 8,406 shares during the period. Northern Trust Corp lifted its holdings in Quest Diagnostics by 0.6% in the first quarter. MD now owns 1,692,947 shares of the medical research company’s stock valued at $207,783,000 after acquiring an additional 567,417 shares during the period. MD lifted its holdings in Quest Diagnostics by 50.4% in the third quarter. now owns 3,258,465 shares of the medical research company’s stock valued at $509,754,000 after acquiring an additional 34,947 shares during the period. lifted its holdings in Quest Diagnostics by 1.1% in the fourth quarter.
now owns 14,156,902 shares of the medical research company’s stock valued at $1,736,910,000 after acquiring an additional 90,362 shares during the period. lifted its holdings in Quest Diagnostics by 0.6% in the third quarter. Empowered Funds LLC’s holdings in Quest Diagnostics were worth $1,263,000 as of its most recent filing with the Securities and Exchange Commission (SEC).Ī number of other institutional investors also recently bought and sold shares of the company. The institutional investor owned 8,924 shares of the medical research company’s stock after purchasing an additional 769 shares during the quarter. Empowered Funds LLC increased its holdings in shares of Quest Diagnostics Incorporated ( NYSE:DGX – Get Rating) by 9.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
0 kommentar(er)
